Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800090 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL5182292 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL119475 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29352431 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29908079 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29682425 | 1.00 | MDM4 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL27435787 | 0.94 | MDM2 (0.56) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL29694496 | 0.93 | PTPN1 (0.58) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL30929979 | 0.92 | TLR2 (0.49) | MDM4TP53TLR2MDM2KMT2A | |
| SCHEMBL30255589 | 0.92 | TLR2 (0.49) | MDM4TP53TLR2MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486304-B2 | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof | C-BIOMEX CO., LTD. (KR) | 2025-12-02 | — | — | US | disclosed |
| US-12435108-B2 | Teixobactin analogue and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-10-07 | — | — | US | disclosed |
| US-20250270257-A1 | PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOF | C-BIOMEX CO., LTD. (KR) | 2025-08-28 | — | — | US | disclosed |
| WO-2025089217-A1 | COMPOUND FOR USE AS SUBSTRATE FOR EVALUATING ACTIVITY OF γ-D-GLUTAMYL-L-LYSYL ENDOPEPTIDASE | 株式会社ヤクルト本社 | 2025-05-01 | — | — | WO | disclosed |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-117120458-B | Peptide ligands targeting carbonic anhydrase IX, peptide structures comprising the same, and uses thereof | C-比奥麦克斯有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119638792-A | Polypeptide PT-09014 and application thereof in antitumor drugs | 科通诺贝生物医药科技(北京)有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119504947-A | Polypeptide PT-1323 and application thereof in antitumor drugs | 科通诺贝生物医药科技(北京)有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119320430-A | Polypeptide PT-1509 and application thereof in antitumor drugs | 科通诺贝生物医药科技(北京)有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-112300247-B | Teixobactin analogue and application thereof | 广东东阳光药业有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-4091623-A1 | CALCIUM-SENSING RECEPTOR AGONIST COMPOUND AND APPLICATION THEREOF | Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| EP-4063378-A1 | BIOLOGICAL PEPTIDE FOR TREATING LUNG DISEASES AND APPLICATION THEREOF | Shanghai Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2022-09-28 | — | — | EP | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-20220273760-A1 | A TEIXOBACTIN ANALOGUE AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-09-01 | — | — | US | disclosed |
| CN-112920256-B | Biological peptide for treating asthma and application thereof | 上海医药工业研究院 | 2022-08-19 | — | — | CN | disclosed |
| CN-112500457-B | Dual-targeting FOXM1/CDK1 anti-tumor polypeptide | 长沙新生康源生物医药有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-4004015-A1 | A TEIXOBACTIN ANALOGUE AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-06-01 | — | — | EP | disclosed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | MDM4 1699/4885TP53 732/4885TLR2 4868/4885 |
| US-20220273760-A1 | A TEIXOBACTIN ANALOGUE AND USE THEREOF | TALDO1, NAMPT, TES | MDM4 3126/4885TP53 1519/4885TLR2 469/4885 |
| US-20250270257-A1 | PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOF | CA9, CA4, CA12 | MDM4 3083/4885TP53 1936/4885TLR2 3372/4885 |
| US-12187816-B2 | Macrocyclic compounds and methods of use thereof | PAICS, CYCS, LSS | MDM4 1699/4885TP53 732/4885TLR2 4868/4885 |
| US-20250129125-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | MDM4 1699/4885TP53 732/4885TLR2 4868/4885 |
| US-12486304-B2 | Peptide ligand targeting carbonic anhydrase IX, peptide construct comprising same, and uses thereof | CA9, CA4, CA12 | MDM4 3083/4885TP53 1936/4885TLR2 3372/4885 |
| US-12435108-B2 | Teixobactin analogue and use thereof | TALDO1, NAMPT, TES | MDM4 3019/4885TP53 1531/4885TLR2 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.